Cargando…

Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.

The relationship between interleukin 6 (IL-6) levels and clinical parameters was studied in 25 patients with malignant pleural mesothelioma. The serum levels of IL-6, C-reactive protein, alpha1-acid glycoprotein and fibrinogen were significantly higher in mesothelioma than in lung adenocarcinoma wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, T., Chahinian, A. P., Shinjo, M., Tonomura, A., Miyake, M., Togawa, N., Ninomiya, K., Higashino, K.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150109/
https://www.ncbi.nlm.nih.gov/pubmed/9528833
_version_ 1782144575790383104
author Nakano, T.
Chahinian, A. P.
Shinjo, M.
Tonomura, A.
Miyake, M.
Togawa, N.
Ninomiya, K.
Higashino, K.
author_facet Nakano, T.
Chahinian, A. P.
Shinjo, M.
Tonomura, A.
Miyake, M.
Togawa, N.
Ninomiya, K.
Higashino, K.
author_sort Nakano, T.
collection PubMed
description The relationship between interleukin 6 (IL-6) levels and clinical parameters was studied in 25 patients with malignant pleural mesothelioma. The serum levels of IL-6, C-reactive protein, alpha1-acid glycoprotein and fibrinogen were significantly higher in mesothelioma than in lung adenocarcinoma with cytology-positive pleural effusion. Serum IL-6 levels correlated with the levels of the acute-phase proteins. We demonstrated a high incidence of thrombocytosis (48%) and a significant correlation between platelet count and the serum IL-6 level. The level of IL-6 in the pleural fluid of patients with mesothelioma was significantly higher than in the pleural fluid of patients with adenocarcinoma, and was about 60-1400 times higher than in the serum. However, even higher levels of IL-6 in the pleural fluid and of thrombocytosis were found in patients with tuberculous pleurisy. These results indicate that large amounts of IL-6 from the pleural fluid of patients with mesothelioma leak into the systemic circulation and induce clinical inflammatory reactions. These profiles are not specific to mesothelioma as similar profiles are found in patients with tuberculous pleurisy. However, the detection of a markedly increased level of IL-6 in pleural fluid argues against a diagnosis of adenocarcinoma.
format Text
id pubmed-2150109
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-21501092009-09-10 Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Nakano, T. Chahinian, A. P. Shinjo, M. Tonomura, A. Miyake, M. Togawa, N. Ninomiya, K. Higashino, K. Br J Cancer Research Article The relationship between interleukin 6 (IL-6) levels and clinical parameters was studied in 25 patients with malignant pleural mesothelioma. The serum levels of IL-6, C-reactive protein, alpha1-acid glycoprotein and fibrinogen were significantly higher in mesothelioma than in lung adenocarcinoma with cytology-positive pleural effusion. Serum IL-6 levels correlated with the levels of the acute-phase proteins. We demonstrated a high incidence of thrombocytosis (48%) and a significant correlation between platelet count and the serum IL-6 level. The level of IL-6 in the pleural fluid of patients with mesothelioma was significantly higher than in the pleural fluid of patients with adenocarcinoma, and was about 60-1400 times higher than in the serum. However, even higher levels of IL-6 in the pleural fluid and of thrombocytosis were found in patients with tuberculous pleurisy. These results indicate that large amounts of IL-6 from the pleural fluid of patients with mesothelioma leak into the systemic circulation and induce clinical inflammatory reactions. These profiles are not specific to mesothelioma as similar profiles are found in patients with tuberculous pleurisy. However, the detection of a markedly increased level of IL-6 in pleural fluid argues against a diagnosis of adenocarcinoma. Nature Publishing Group 1998-03 /pmc/articles/PMC2150109/ /pubmed/9528833 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Nakano, T.
Chahinian, A. P.
Shinjo, M.
Tonomura, A.
Miyake, M.
Togawa, N.
Ninomiya, K.
Higashino, K.
Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
title Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
title_full Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
title_fullStr Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
title_full_unstemmed Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
title_short Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
title_sort interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150109/
https://www.ncbi.nlm.nih.gov/pubmed/9528833
work_keys_str_mv AT nakanot interleukin6anditsrelationshiptoclinicalparametersinpatientswithmalignantpleuralmesothelioma
AT chahinianap interleukin6anditsrelationshiptoclinicalparametersinpatientswithmalignantpleuralmesothelioma
AT shinjom interleukin6anditsrelationshiptoclinicalparametersinpatientswithmalignantpleuralmesothelioma
AT tonomuraa interleukin6anditsrelationshiptoclinicalparametersinpatientswithmalignantpleuralmesothelioma
AT miyakem interleukin6anditsrelationshiptoclinicalparametersinpatientswithmalignantpleuralmesothelioma
AT togawan interleukin6anditsrelationshiptoclinicalparametersinpatientswithmalignantpleuralmesothelioma
AT ninomiyak interleukin6anditsrelationshiptoclinicalparametersinpatientswithmalignantpleuralmesothelioma
AT higashinok interleukin6anditsrelationshiptoclinicalparametersinpatientswithmalignantpleuralmesothelioma